 
Introduction
Every year cancer of the cervix (cervical cancer) is diagnosed in about 500 000 women, causing approximately 250 000 deaths annually [1, 2] . The high-risk types of human papillomavirus (HPV) are associated with over 80% of cervical cancers through epidemiological and experimental studies [3] . Two high-risk types, HPV type and HPV type 18 (HPV-18), are responsible for up to 50% and 20% of all cervical cancers, respectively [4] . The traditional detection of cervical pre-cancers by cervical cytological screening using the Papanicolaou (Pap) smear test has dramatically reduced the incidence of cervical cancer in the developed world due to early intervention with therapy. However, underdeveloped countries are unable to implement comprehensive screening-based programs, so early detection and treatment of cervical pre-cancers is very limited [5, 6] . Patients who are diagnosed with early-stage disease can be treated with surgery, radiotherapy, or chemotherapy, but many patients still succumb to the disease [6, 7] . It is therefore necessary to develop more effective therapies for the treatment of cervical cancer. cancers by approximately 70% [8] [9] [10] [11] . Despite the successful prophylactic effects of these vaccines, the high cost, cold storage requirement, and availability of the existing prophylactic HPV vaccines are important limitations to the widespread delivery of these vaccines in developing countries. Thus, the prevalence and associated morbidity of cervical cancer may not be significantly reduced worldwide [12] [13] [14] . Prophylactic HPV vaccines that target the L1
capsid have no therapeutic effect on established HPV infection. This is because HPV-infected basal epithelial cells and cervical cancer cells do not express detectable levels of L1 capsid antigen. The time between virus infection and tumor development is typically 10-20 years, so a large proportion of the global population is already infected and cannot be treated by the prophylactic vaccine [11, 12, 15, 16] . To combat established infections, it is necessary to develop a therapeutic vaccine against high-risk HPV, particularly HPV-16 and HPV-18
strains [17] [18] [19] . Since T cells can recognize tumor-associated antigens in the form of short peptides bound to major histocompatibility complex (MHC) molecules, vaccination with peptides derived from HPV antigens provides a feasible strategy for immunotherapy against HPV infections [23, 24] . Identification of tumor-reactive T lymphocyte peptide epitopes is necessary before a vaccine can be developed. Peptide-based vaccines have the potential advantages of combining multiple epitopes to enhance peptide-MHC binding and improve specific T cellmediated immunity against HPV-infected cells [25] . However, selection of the most appropriate T cell epitopes able to elicit responses by antitumor cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) remains a challenge. Another limitation is that peptide-based vaccines have low immunogenicity. Many developments in the use of peptidebased vaccines have focused on enhancing vaccine potency by using adjuvants (immune stimulating agents) to circumvent this problem [26] . This review summarizes the prospects of peptide-based vaccines for the treatment of established HPV infections. We address the obstacles that scientists currently face in developing peptide-based vaccines and explore feasible strategies for improving the potency of inducing immune responses leading to the treatment of HPV infections.
The biology of HPV infection in the cervix
In order to develop an optimal therapeutic vaccine against HPV, it is necessary to fully understand the progression from HPV infection to cervical cancer. HPV belongs to a genus in the Papovirus family and is a non-enveloped, double-stranded, closed circular DNA virus.
The HPV genome is approximately 8,000 base pairs, encoding six early proteins (E1, E2, E4, E5, E6, and E7) and two late proteins (L1 and L2) [27] . [28, 29] . Interactions between HPV proteins and the host cell result in dysregulation of cell cycle control, eventually leading to the development of cervical cancer.
The infection of the cervical epithelium with HPV is closely associated with the maturation of keratinocytes (Figure 2 ). After infection with HPV in the basal layer of the epithelium, the viral early proteins are expressed, and interact with cellular proteins to regulate viral replication. Next, the infected basal cells move up from the basement membrane to the upper epithelial layers as epithelial cell differentiation occurs, expressing E4 protein for viral amplification. Finally, a subset of E4-positive cells express the late proteins L1 (major) and L2 (minor), and L1 and L2 assemble to form the new infectious virions. Therefore, mature virions are released only by the superficial epithelial keratinocytes [27] .
Integration of the viral episome into the host DNA occurs in cells infected with high risk HPV. This often results in the deletion or inactivation of some early (E2, E4 and E5) and late (L1 and L2) genes, while the E6 and E7 genes are consistently expressed within infected cells [13, 14] . The viral E2 gene is a negative regulator of E6 and E7 expression. Subsequently, interruption of E2 gene leads to over expression of the E6 and E7 genes [30] . In addition, the E6 and E7 genes are able to bind and complex with the tumor suppressor gene products, p53
and retinoblastoma (pRb) protein, respectively. p53 and pRb have tumor-suppressive and cell cycle growth inhibitory functions [31, 32] . Thus, over-expression of E6 and E7 oncoproteins results in the dysregulation of the cell cycle, causing cellular transformation which leads to the development of cervical intraepithelial neoplasia (CIN) that may eventually progress to cervical cancer [33] . (1) Humoral immunodeficiency does not predispose HPV-positive patients to the growth of HPV-associated, pre-cancerous lesions.
Humoral immune responses and cell-mediated immune responses to HPV infections
(2) The prevalence of HPV-associated disease is increased in patients with reduced CD4 + T cell function, such as transplant recipients [44] and human immunodeficiency virus (HIV)-infected patients [45, 46] . (1) The HPV-16 E7 oncoprotein has high homology with several human proteins [57] , which may facilitate recognition as autoantigen.
(2) The E6 oncoprotein inhibits the interactions between epithelial cells and DCs [58] , possibly accounting for the depletion of DCs observed in the HPV-infected cervical epithelium [59] . An E6 oncoprotein-mediated reduction in expressed interleukin-8
(IL-18) CD8 + was also observed [60] .
(3) The E6 and E7 oncoproteins down-regulate the production and responsiveness of infected cells to type 1-interferons (IFNs) [61, 62] . Both E6 and E7 oncoproteins inhibit IL-18-induced IFN-γ in natural killer (NK) cells [63] . Additionally the E7 oncoprotein arrests the antiviral signaling mediated by interferon-alpha (IFN-α) [64, 65] and has also been observed to inhibit the IRF-1-mediated activation of the IFN-β promoter [66] .
(4) Extracellular E7 oncoprotein potentially has the ability to inhibit T cell responses [67] .
(5) The E5 oncoprotein binds the 16-kDa subunit of vacuolar proton-ATPase and disturbs its activity, inhibiting pH-dependent processing of antigenic peptides, which may interfere with proper antigen presentation [68] [69] [70] .
Cervical cancer has been shown in the past to inactivate the type 1 interferons (IFNs), cytokines such as IL-18, and antigen processing and presentation. A recent study has revealed that cervical extracts, in particular the protease component, can suppress lympho-proliferative responses [71] , whereas expression of FasL on cervical tumors can cause apoptosis of the infiltrating lymphocytes [72] . These results also indicate that the production of regulatory T cells may be an important suppressive mechanism in cervical cancer [73, 74] , because regulatory T cells suppress the induction of type 1-helper T (Th1) cells [75] , and IFN-γ-producing Th cells are required to mobilize CD8 + T cells to the site of HPV infection [76] .
Therefore, a successful immunotherapeutic approach to cervical cancer must circumvent the activity of these cells types and other local immunosuppressive mechanisms. oncoproteins are required for the induction and maintenance of the malignant phenotype of cancer cells [81] , cervical cancer cells are unlikely to escape immune attack targeting these proteins via antigen loss. The E7 protein is more abundantly expressed and is more highly conserved than the E6 protein [82, 83] . The E7 protein also induces genotype-specific antibody after the commencement of invasive cervical cancer, thus the E7 proteins can generate therapeutic and protective effects [82] . Other early viral proteins, the E1, E2, E4, and E5 proteins, also have potential as therapeutic vaccine antigens for the treatment of warts.
Therapeutic HPV vaccine development
However, neither the E1 protein nor the E2 protein is constantly expressed in HPV-induced carcinoma. Evidence suggests that E5 may play a critical role in the genesis of cervical cancer but is less important in persistence and progression [84] . Therefore, the E5 protein has limited immunogenicity and has not been extensively researched as a promising vaccine antigen [85] . Similarly, the E4 protein and L1 and L2 capsid proteins are unlikely to be proper targets for therapeutic vaccine antigens because these proteins are not expressed at detectable level in infected basal epithelial cells and cervical cancer cells [86] .
In order to treat patients with pre-invasive and invasive cervical cancers, therapeutic vaccines need to elicit specific cytotoxic anti-tumor responses by targeting CD8 + T cell activation via MHC-I restricted antigens. Additionally, CD4 + T cell responses, which are MHC-II restricted, are equally important in both effective anti-viral and antitumor CTL responses, and lead to destruction of the virus or tumor by CD8 + CTLs [87, 88] . The function of CD4 + T cells in the priming phase of a tumor specific CTL response is thought to occur at the level of activating DCs to allow these cells to effectively activate naive CD8 + T cells [89] [90] [91] .
Consequently, several requirements need to be met for the establishment of an effective therapeutic vaccine against cervical cancers:
(1) The target antigen must be recognized by the T cells rather than by antibodies.
(2) The vaccine should target appropriate APC subsets. (6) Induce strong, long-lasting inflammation at the tumor site.
Several HPV vaccine strategies have been devised to achieve these requirements with different degrees of success. Peptide-based vaccines are one of the most promising approaches to develop a safe and efficient therapeutic vaccine to treat HPV-related cancers.
Peptide-based HPV vaccine development
Synthetic peptide-based vaccines are potentially excellent candidates for rational vaccine development because they are naturally non-infectious, completely defined, relatively easy to produce, and are generally considered to be safe. Peptide-based vaccines are well characterized, stable in freeze-dried form, and are able to combine multiple epitopes [20, 22, 25] . However, their low immunogenicity must first be overcome. Another limitation of peptide-based vaccines is the need to match the patient's human leukocyte antigen (HLA).
HLA polymorphisms in patients make it difficult to develop a peptide-based vaccine that is applicable to the whole population. In the case of peptide-based vaccines against HPV, several specific CTL epitopes from HPV-16 E6 and E7 have been characterized for the HLA-A2 molecule, the most common MHC-I molecule in humans [92] [93] [94] . Immunization with a peptide carrying MHC-I restricted epitopes from E6 and/or E7 have been shown to elicit cellmediated immune responses in both animal and human models [92, 94] . In addition to finding an epitope that interacts with the host HLA, the design of a peptide-based anti-HPV vaccine relies on the accurate identification of an appropriate protective epitope.
Epitope selection
Epitope identification and selection of most relevant epitopes are the initial challenges of peptide-based vaccine development. 
Vaccine delivery
In general, peptide-based vaccines have weak immunogenicity, but the use of adjuvants (immune stimulating agents) can boost the immunogenicity of these vaccines [22] . A number of adjuvants induce strong immune responses and are widely used in animal models (e.g. from its propensity to target vaccines to DCs and induce DC maturation [22, 112] . In another mouse study, a lipopeptide vaccine incorporated the E6 [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] and E7 [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] epitopes conjugated to a dipalmitoyl-lysine-glycine-glycine (Pam 2 KGG) moiety. It was shown that although both epitopes were individually able to elicit specific CTL responses in mice, the lipid-tailed (Pam 2 KGG) diepitopic construct was more efficient than the monomeric forms [113] .
Liposomes have been used extensively to deliver low molecular weight drugs, plasmid DNA, oligonucleotides, proteins, and peptides as well as for the delivery of peptide-based antigens.
Huang and coworkers developed a liposome-based, nanoparticle delivery system, called
Liposome-Protamin-DNA (LPD) [114] . LPD is a self-assembled mixture of cationic liposomes, polycations, and plasmid DNA. In their early studies, the LPD/E7 formulation A (MPL) [100] . A recombinant cytokine, e.g. granulocyte-macrophage colony-stimulating factor (GM-CSF), can be used as an adjuvant for augmenting immunogenicity in peptidebased vaccines [100, 119] . In one of the latest studies, a self-assembled nanoparticle HPV vaccine was designed to combine the cell-penetrating peptide, HIV-1 Tat bacterial DNA and binds toll-like receptor (TLR)-9 providing a "danger signal" to activate the immune response [120] . Therefore, vaccination with a long peptide containing CD8 + CTL and CD4 + Th cell epitopes, and DC-activating agents could augment the immunity generated against peptide-based HPV vaccines [100] . A similar long peptide and adjuvant combination was also trialed in the cottontail rabbit papillomavirus (CRPV) preclinical model of persistent HPV infection. Overlapping long E6 and E7 peptides, which contained both CD4 + T helper and CD8 + CTL epitopes, administered with the mixture of Montanide ISA 51 and ODN-CpG were tested for therapeutic efficacy against CRPV-infected lesions. After vaccination, this overlapping long vaccine was able to significantly control wart growth in rabbits [98] .
Another animal study, which used a long peptide (E7 [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] ) and the DC-activating adjuvant ODN-CpG, has identified that vaccination with a longer peptide containing CTL and Th cell epitopes, and ODN-CpG represents a promising strategy against MHC-I deficient tumors.
This study also investigated the efficacy of cellular vaccines based on ex vivo cultured DCs pulsed with either minimal CTL (E7 [49] [50] [51] [52] [53] [54] [55] [56] [57] ) epitope or longer CTL (E7 [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] peptide antigens to trigger immune responses. It was revealed that longer peptides presented by ex vivo cultured DCs resulted in stronger inhibition of tumor growth than the shorter epitopes [116] .
In recent years, several novel vaccine delivery platforms were developed for augmenting the immunogenicity of peptide-based vaccines. Daftarian and coworkers encapsulated antigens and adjuvants in multilamellar liposomes in a water-in-oil emulsion, VacciMax  (VM) [117] .
VM is a liposome-based antigen delivery platform containing the Pan HLA-DR epitope (PADRE) and ODN-CpG as adjuvants and Montanide ISA 51 as the oil carrier of the waterin-oil emulsion. PADRE, a universal T helper epitope, was found to bind to different MHC-II molecules with high-affinity and was used in conjunction with other types of vaccines to increase vaccine potency in preclinical studies [121, 122] . In a preclinical study using the C3 tumor model, a single administration of a minimal CTL (E7 [49] [50] [51] [52] [53] [54] [55] [56] [57] ) epitope via VM liposomebased antigen delivery induced a long-lasting CTL response, complete protection against tumor challenge, and rapid tumor eradication. All mice that received this vaccine remained tumor-free when re-challenged with C3 cells [117] . To extend these results to a more Therefore, VM is a promising vaccine delivery platform for the therapeutic treatment of cervical cancer [118] .
Another animal study, using a similar strategy, combined the PADRE peptide (to enhance with E7 peptide in combination with PADRE and poly(I:C) generated better CD8 + T cell immune responses when compared with subcutaneous vaccination [123] . Combining a long CTL (E [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] ) epitope with poly(I:C) and the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA), has also been shown to enhance the E7 specific CD8 + T cell immune responses. Interestingly, the timing/treatment regimen of DMXAA administration played an important role in vaccine efficacy [124] . The transmission of HPV-16 is mainly via the genital mucosal route, thus mucosal immune responses are of interest when developing vaccination strategies against HPV. The therapeutic vaccine that codelivered peptides from HPV-16 E7 [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] and E6 [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] proteins, along with the non-toxic mucosal adjuvant CT-2* generated strong systemic and mucosal cellular immunity, along with anti-tumor efficacy [125] .
Human trials of immunotherapy for HPV infection
Several peptide-based therapeutic HPV vaccines have been evaluated to be safe and well tolerated in early phase I/II clinical trials ( [126] . Phase I/II trials have also tested two HPV-16 peptides, E7 [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and E7 [86] [87] [88] [89] [90] [91] [92] [93] , and a PADRE emulsion in the Montanide ISA 51 adjuvant in patients with recurrent or refractory cervical cancer [105, 106] . This therapeutic vaccine showed no significant adverse effects in both trials. In the phase I study, 2 out of 19 patients showed tumor-regression after chemotherapy following vaccination [105] . In the phase II trial, 2 out of 15 patients had diseased states that were unchanged more than 1 year after vaccination [106] . Based on these studies, it was suggested that vaccination of patients with less advanced cervical disease might be more effective [105, 106] . Therefore, a vaccine candidate in patients with earlier stages of HPV-induced disease was tested in a phase I trial 
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+ dendritic cell infiltrate was observed in 6 out of 6 patients tested. Overall, these peptide-based vaccines were more effective in women who had early stage cervical cancer than in women whose immune systems were compromised by progressive disease [107] .
A strategy that enhances immune responses to peptide-based vaccines by using a long months. These responses were maintained at 24 months follow-up [103] . Overall, the overlapping long peptides vaccine offers a promising strategy for the treatment of women who are in earlier stages of HPV-induced disease.
Conclusion
Although commercial preventive or prophylactic HPV vaccines are now available and have the potential to prevent the onset of cervical cancer and other HPV-associated malignancies, it is predicted that it will take decades to significantly reduce the prevalence of cervical cancer. Additionally, the full effect of the new prophylactic HPV vaccines on cervical cancer incidence can only be evaluated decades after implementation. Thus, development in the meantime of a therapeutic HPV vaccine that is safe, economical, and effective is a priority. 
